Related Experiment Video
Updated: Jul 9, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Gazing into the future: Parkinson's disease gene therapeutics to modify natural history
Kathleen A Maguire-Zeiss1, Timothy R Mhyre, Howard J Federoff
1Department of Neuroscience, Georgetown University, Washington, DC 20007, USA.
Abstract:
PD gene therapy clinical trials have primarily focused on increasing the production of dopamine (DA) through supplemental amino acid decarboxylase (AADC) expression, neurotrophic support for surviving dopaminergic neurons (DAN) or altering brain circuitry to compensate for DA neuron loss. The future of PD gene therapy will depend upon resolving a number of important issues that are discussed in this special issue. Of particular importance is the identification of novel targets that are amenable to early intervention prior to the substantial loss of DAN. However, for the most part the etiopathogenesis of PD is unknown making early intervention a challenge and the development of early biomarker diagnostics imperative.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology
Parkinson's Disease: Overview
Parkinson Disease l: Introduction
Pharmacogenomics: Identification of New Drug Targets
Gene Therapy
